Pralmorelin

Drug Profile

Pralmorelin

Alternative Names: GHRP-2; GPA 748; Growth hormone releasing peptide 2; KP-102 D; KP-102 LN

Latest Information Update: 02 Jun 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Polygen; Tulane University
  • Developer Kaken Pharmaceutical; Wyeth
  • Class Peptide diagnostics
  • Mechanism of Action Ghrelin receptor agonists; Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Discontinued Short stature

Most Recent Events

  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 12 Sep 2007 Pralmorelin is still in phase II trials for Short Stature in Japan
  • 14 Mar 2005 Launched for Somatropin deficiency (diagnosis) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top